- Home
- SEV vs CRBP Comparison
SEV vs CRBP Comparison
Compare SEV & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEV | CRBP |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 134.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SEV | CRBP |
|---|---|---|
| Price | $3.81 | $10.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $46.17 |
| AVG Volume (30 Days) | ★ 406.6K | 152.1K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.29 | $4.64 |
| 52 Week High | $11.24 | $20.56 |
Technical Indicators
Market Signals| Indicator | SEV | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 72.63 | 70.35 |
| Support Level | $1.29 | $9.86 |
| Resistance Level | $5.09 | $11.64 |
| Average True Range (ATR) | 0.35 | 0.58 |
| MACD | 0.26 | 0.24 |
| Stochastic Oscillator | 96.30 | 96.56 |
Price Performance
Historical ComparisonAbout SEV Aptera Motors Corp.
Aptera Motors Corp develops and produces energy-efficient solar-powered, battery-electric vehicles designed to maximize solar energy utilization. The company focuses on lightweight composite structures and solar technology to minimize environmental impact and reduce reliance on charging infrastructure.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.